Topaz Pharmaceuticals Inc., a Philadelphia-based pediatric drug company, has raised $20 million in Series A funding from Aisling Capital and Fidelity Biosciences. Seaview Securities LLC served as financial advisor.
Topaz Pharmaceuticals, a pharmaceutical company dedicated to the health and well being of children, today announced that it has secured $20 million in Series A financing from Aisling Capital (
Topaz is developing its lead product to give healthcare professionals a new choice to treat head lice infestations which are becoming more resistant to some traditional treatments. Between 6 and 12 million children are affected by head lice in the
“This round of funding is a significant milestone in the evolution of Topaz Pharmaceuticals Inc.,“ said
This latest round of funding was conducted with financial advice from Seaview Securities LLC and advised by Fox Rothschild LLP's Technology and Venture Finance Group.
About Topaz Pharmaceuticals
Topaz Pharmaceuticals Inc., an early stage company, intends to develop a range of pediatric medicines. Its initial lead product is a novel and kid friendly formulation of an active ingredient derived from a naturally occurring soil organism that is lethal to head lice. Topaz initially benefited from support provided by the Ben Franklin Technology Partners of Southeast Pennsylvania. For more information about Topaz Pharmaceuticals Inc. please visit www.topazpharma.com.